As the COVID-19 situation develops, tax and regulatory specialists within the pharmaceutical & life sciences industry are increasingly facing complex challenges. Efficient and pragmatic solutions have to be realised, with fewer resources, in line with the changing local legislation.
The exchange of information is the best practice in this industry to support and inspire you in your daily business.
In light of that, we would like to invite you to our Pharma & Life Science webinar where we and other industry professionals will be discussing the impact of COVID-19 on the ITX and regulatory DNA on the pharma and life science industry.
We will be talking about VAT, regulatory and export control topics in the pharmaceutical and life science business concentrating on Risks and Opportunities, which impact national and international sale of drugs, precision medicines, clinical trials and technology.
I look forward to welcoming you to our webinar.
| Date | Thursday 28. May 2020 |
| Time | 10.30am – 11.15am (CEST) |
Speakers
| Dr. Sandra Ragaz-Fumia | Partner Leader Pharma & Life Science VAT PwC Switzerland |
| Christine Frankenberger | Manager, Export Controls Customs & International Trade PwC Switzerland |
Agenda
| 10:30 | Welcome |
| 10:35 | Required VAT documentation for Clinical Trials in Europe during COVID-19 |
| 10:45 | COVID-19 and impact on EU GMP Annex 21 for the sale of pharmaceuticals |
| 10:55 | Precision medicines and COVID-19 – VAT and export control consideration |
| 11:05 | Q&A Session and Closing |
Michaela Merz 